Generic Cosmetics raises follow-on from Vision Platform
What's the deal? Generic CosmeticsDealroom has a profile for this one. Try Dealroom → (ジェネリック化粧品), a Japanese startup that develops and sells high-quality skincare and cosmetics at accessible prices, has closed a new funding round from its existing investor Vision PlatformDealroom has a profile for this one. Try Dealroom →. The company did not disclose the amount raised.
Founded in 2021 and based in Kofu, Yamanashi Prefecture, Generic Cosmetics holds the only registered trademarks in Japan for "generic cosmetics" and "generic cosme." The round was structured as a shareholder allotment — a follow-on investment from Vision Platform, which first backed the company in 2025.
Why now? Since Vision Platform's initial investment, Generic Cosmetics has grown revenue and its member base more than five-fold in roughly one year. It has also expanded its product lineup steadily during that period.
The fresh capital will go towards product development, brand awareness, and marketing. The company also plans to enter new product categories and sales channels, leveraging Vision Platform's expertise in management, marketing, and technology.
What could go wrong? The "generic" positioning — offering comparable quality at lower prices — is a compelling pitch, but Japan's beauty market is fiercely competitive. Established players and other affordable brands could squeeze margins or outspend Generic Cosmetics on marketing. Without a disclosed funding amount, it is hard to gauge how much runway the startup actually has.
Scaling beyond a direct-to-consumer model into new channels also brings operational complexity, from retail partnerships to inventory management.
The signal: Vision Platform's decision to double down via a shareholder allotment — rather than bringing in new investors — suggests the corporate backer sees enough in Generic Cosmetics' five-fold revenue jump to deepen its bet at the early growth stage. Japan's beauty market is enormous but notoriously brand-loyal, so the real test is whether a "generic" value proposition, already proven in pharmaceuticals, can convert enough consumers to sustain that trajectory beyond a single investor's support.
Read more: prtimes.jp
